Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS: AR101 in Peanut-Allergic Children
NCT03201003Phase 3Completed
- Start
- Jun 2017
- Primary completion
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Allergy Immunotherapy
- Countries
- 7
01
Overview
A Phase 3 trial of peanut protein in peanut allergy. Started Jun 2017; status: completed.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03201003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03201003.